Company / Cash & Equivalents
Nuo Therapeutics, Inc. Cash & Equivalents History
FY2013-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$693.5K
FY2017
5-year range
$693.5K / $15.9M
FY2013-FY2017
Trend
-93.3%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 5 years, ranging from $693,515 in FY2017 to $16M in FY2014.
Based on SEC 10-K filings.
$693,515 in FY2017 with a 3-year CAGR of -64.8%.
Declined from $922,317 to $693,515 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -64.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -64.8%, indicating a declining trend.
- In FY2017, cash & equivalents decreased 93.3% year-over-year.
- Peak cash & equivalents was recorded in FY2014.
Company context
Key Data Points
- Altman Z-Score -45.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2017 | $693.5K | -93.3% |
| FY2016 | $10.4M | +1023.1% |
| FY2015 | $922.3K | -94.2% |
| FY2014 | $15.9M | +385.2% |
| FY2013 | $3.3M | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2017 · SEC 10-K · Updated Jun 29, 2026